TriangleIomab-B Followed by CAR-T Cell Therapy (NCT06768905)
Iomab-B Followed by CAR-T Cell Therapy trial for Non Hodgkin Lymphoma (NCT06768905). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for large B-cell lymphoma that has returned or not responded to earlier treatment, in patients who are candidates for standard CAR T therapy.
The idea: change the preparation step. A single dose of a radioactive medicine, iodine-131 apamistamab, is given five to seven days before the CAR T infusion, for lymphodepleting conditioning. Actinium Pharmaceuticals is listed as a collaborator. The CAR T product itself is an approved one.
The first six patients form a safety run-in. At UT Southwestern in Dallas, Farrukh Awan leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.